Development of a Grp94 inhibitor. - Wikidata - wikimedia - TriplyDB

Development of a Grp94 inhibitor.

Development of a Grp94 inhibitor.

http://www.wikidata.org/entity/Q39340802

about

Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 Synthesis of benzoquinone ansamycin-inspired macrocyclic lactams from shikimic acid Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94 Selective targeting of the stress chaperome as a therapeutic strategy Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β Targeted deletion of ER chaperone GRP94 in the liver results in injury, repopulation of GRP94-positive hepatocytes, and spontaneous hepatocellular carcinoma development in aged mice Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94 The role of glycoprotein 96 in the persistent inflammation of rheumatoid arthritis.Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.Grp94 Protein Delivers γ-Aminobutyric Acid Type A (GABAA) Receptors to Hrd1 Protein-mediated Endoplasmic Reticulum-associated Degradation.A Human Variant of Glucose-Regulated Protein 94 That Inefficiently Supports IGF Production.Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold Napyradiomycins CNQ525.510B and A80915C target the Hsp90 paralogue Grp94.The role of heat shock protein 90 in modulating ischemia-reperfusion injury in the kidney.Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?Targeting the unfolded protein response for disease intervention.Targeting the ER-autophagy system in the trabecular meshwork to treat glaucoma Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.Glucose-regulated protein 94 mediates metastasis by CCT8 and the JNK pathway in hepatocellular carcinoma.Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma.Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway.Development of radamide analogs as Grp94 inhibitors Alternative approaches to Hsp90 modulation for the treatment of cancer.HSP90: a promising broad-spectrum antiviral drug target.Reaction design, discovery, and development as a foundation to function-oriented synthesis.Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma 5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.Resorcinol-Based Grp94-Selective Inhibitors.Adapting Secretory Proteostasis and Function Through the Unfolded Protein Response.Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.

P2860

Q26748800-106C1DFD-C7AC-4CED-B129-79741129EE8E Q27679845-3AC7462E-5D00-4E53-8F79-DD8D32539A05 Q27684361-5C9AB5C5-F2C8-4311-BEB8-78A9AFD44F4F Q28075479-ECA6F166-2BB5-4FFC-9784-245254639628 Q28248791-B55E6CF0-8269-4FF7-9B7C-24FD79AD055C Q28829208-9FCF27C4-572E-4F5A-AB7E-F34001D3F964 Q34529312-9FE03125-D7F8-4240-B213-E3F43971F951 Q35899122-C50C2320-4115-4593-80F6-78723937FDED Q36572635-C92AFB18-C921-4772-939F-1A6263C71C09 Q36655158-CD573184-D383-4AF2-B8D9-D70F82F339D5 Q36850007-79C45734-9C03-4276-96ED-453538ACBEF4 Q36911625-3E0EE573-0E1E-4D97-8278-2368B6A48274 Q37164519-67246A76-4ABA-428F-B9A1-83C2528DE98F Q37486995-ACC73DED-6278-46A4-A509-570713E6EECF Q38033199-A7364845-19E1-462C-82F1-87E90DBCDF8E Q38198491-2A59235A-7304-48E9-B346-0BC79E8374D9 Q38234720-75460C75-6C92-469F-AE12-CB43FE4F8E51 Q38428349-479BD659-087A-4A97-9215-26117C14453A Q38502737-F6A52571-8AF9-4E8E-B614-BD4CA5A3988A Q38545670-CE756AD6-640E-48B8-811D-68DDBBCF0A09 Q38572659-AE2751BE-BF8D-431C-8406-A5175F8B9CE8 Q38735183-1DB7D6C0-1F10-4D0B-8491-99C3C9A48EE9 Q38807896-B752581E-4E0F-4B33-B04D-19B3D011C28C Q38818474-BDAF017F-4EC1-47DC-BA21-61DFFC956E11 Q38825761-E19BFB27-650C-496F-93D6-457E405BD904 Q38860378-7087ECB3-6713-41A8-91C7-933376F02701 Q38975022-475205B7-CBD1-4611-ACC8-9E1F70B02465 Q39103704-BC18B135-6D4B-487B-B832-D5EA52D1A21A Q40093256-DF7D7ADB-A4BA-4093-BE67-A399B66DB4AE Q42045286-2DD9345F-0067-4F81-99FE-08203D44D26C Q42095433-6AA58D43-DD3F-47F5-8156-29FCD0D52448 Q44586980-8790731B-7A43-4BA9-9CB8-63E33E8BBD16 Q47616767-1DF44C9D-7A22-4276-A486-7FD25CB59394 Q47619180-09BCB45F-7D1A-4302-83BB-ADD5DA895C8D Q47774233-04E8AABD-BBDF-4F68-82AB-B0F9B7308A78 Q47878536-D4D0F67A-3FC6-488F-AAA0-3158AE7A0C77 Q48118580-1737C01A-805D-4F32-9F31-0A325228BBA5 Q48160287-E455A236-4612-43F3-8DF1-C63A81FED560 Q48542611-912B306E-92DB-4BE5-943A-3123509D47FB Q49415335-98B10496-75EC-4D5C-A61D-0D8DC6B18B55

P2860

Development of a Grp94 inhibitor.

http://www.wikidata.org/entity/Q39340802

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Development of a Grp94 inhibitor.

@en

Development of a Grp94 inhibitor.

@nl

type

label

Development of a Grp94 inhibitor.

@en

Development of a Grp94 inhibitor.

@nl

prefLabel

Development of a Grp94 inhibitor.

@en

Development of a Grp94 inhibitor.

@nl

P1433

Q39340802-B7C98CE5-67E2-4D74-87BD-696444AF640F

P1476

Q39340802-640F5104-4250-4493-ABA2-EE5E9DBB5D33

P2093

Q39340802-03D0FC2D-C016-43FD-A298-1C108B3A262C

Q39340802-1A0478D0-4EC4-4393-9CDE-8539A04EA0D1

Q39340802-336489F6-4F0E-4FAC-9868-02BBC522280B

Q39340802-4147E02D-434D-455F-BCBE-057625639928

Q39340802-53226EFE-8256-4F68-9BE9-6ECE5B0977EE

Q39340802-5E88224B-2880-49E5-AA0F-75E03FD3A46E

Q39340802-76026C64-EF1B-41B5-95D9-EC846B8E2CF8

Q39340802-B183D123-BA9B-4755-A1BD-3CF7A07A8B02

Q39340802-B7772763-8987-4498-BD99-26DEA623741B

Q39340802-DA9ABB6F-BC1F-4207-87A7-F77D40F700DB

P2860

Q39340802-01088AED-35A5-4143-A42C-F0904EA84E69

Q39340802-06231F71-8B45-48A8-839E-B367A392D50D

Q39340802-0BAEAF80-7118-41B4-A171-46A7534BEED2

Q39340802-0F0C5CDD-5F37-43D2-AA98-D186225BB35E

Q39340802-0F7C1A29-18E2-4F33-820B-5577761E7E25

Q39340802-1399BF9A-4A7B-4C80-A0CF-439BC066CC4C

Q39340802-15ED923C-64C8-4BE3-B24C-2C8807ED9A1D

Q39340802-15EFCCD7-1B59-45B6-8D14-69C4E4C25C66

Q39340802-1D6F90A6-D913-40A6-B173-8F5919CD1D42

Q39340802-23E41A76-2CDE-4CEA-8347-6699B4B2984D

P304

Q39340802-CCBE5694-8341-4D67-AE03-8F9DEF77FB84

P31

Q39340802-DE20048D-2B8B-4430-A4E8-389A18A0757A

P356

Q39340802-8746C7DC-511D-4892-91C0-DA3F6B15407A

P407

Q39340802-334D1EA6-D025-4BE9-A5F1-C4E9EAA2AA89

P433

Q39340802-D0889632-B77D-4F83-92E0-D0A762A08EF0

P478

Q39340802-77B64A75-8CD6-4FBE-9051-C6DE79A88252

P577

Q39340802-1A626BB2-F64E-4DCC-83D6-B48FAF15265C

P5875

Q39340802-1EB6DD00-A67D-47E3-818C-8AD2AA55C51F

P698

Q39340802-CDDDCE60-40EE-4864-A294-6C2C1766AC31

P932

Q39340802-508B55E1-9FF8-4E49-AE03-CD4AE6FB5C9F

P356

P1433

Journal of the American Chemical Society

P1476

Development of a Grp94 inhibitor.

@en

P2093

Adam S Duerfeldt

http://www.w3.org/2001/XMLSchema#string

Brian S J Blagg

http://www.w3.org/2001/XMLSchema#string

Christopher V Nicchitta

http://www.w3.org/2001/XMLSchema#string

Chun Leung Ng

http://www.w3.org/2001/XMLSchema#string

David S Moore

http://www.w3.org/2001/XMLSchema#string

Davide Eletto

http://www.w3.org/2001/XMLSchema#string

Heather E Shinogle

http://www.w3.org/2001/XMLSchema#string

Jason C Maynard

http://www.w3.org/2001/XMLSchema#string

Laura B Peterson

http://www.w3.org/2001/XMLSchema#string

Olga Ostrovsky

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome

Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages

Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones

CellProfiler: image analysis software for identifying and quantifying cell phenotypes

GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum

Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation

Different Poses for Ligand and Chaperone in Inhibitor-Bound Hsp90 and GRP94: Implications for Paralog-Specific Drug Design

P304

9796-9804

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JA303477G

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225071760

http://www.w3.org/2001/XMLSchema#string

P698

22642269

http://www.w3.org/2001/XMLSchema#string

P932

3414055

http://www.w3.org/2001/XMLSchema#string